Revenue grew 9.5% to $320.2M, led by Med Tech segment growth and improved gross margin, but net loss widened to $36.7M due to higher operating expenses and restructuring. Strategic divestitures and cost-saving initiatives are underway, with strong liquidity and a focus on high-growth platforms.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.